AIMS/HYPOTHESIS: Metabolomics approaches in humans have identified around 40 plasma metabolites associated with insulin resistance (IR) and type 2 diabetes, which often coincide with those for obesity. We aimed to separate diabetes-associated from obesity-associated metabolite alterations in plasma and study the impact of metabolically important tissues on plasma metabolite concentrations. METHODS: Two obese mouse models were studied; one exclusively with obesity (ob/ob) and another with type 2 diabetes (db/db). Both models have impaired leptin signalling as a cause for obesity, but the different genetic backgrounds determine the susceptibility to diabetes. In these mice, we profiled plasma, liver, skeletal muscle and adipose tissue via semi-quantitative GC-MS and quantitative liquid chromatography (LC)-MS/MS for a wide range of metabolites. RESULTS: Metabolite profiling identified 24 metabolites specifically associated with diabetes but not with obesity. Among these are known markers such as 1,5-anhydro-D-sorbitol, 3-hydroxybutyrate and the recently reported marker glyoxylate. New metabolites in the diabetic model were lysine, O-phosphotyrosine and branched-chain fatty acids. We also identified 33 metabolites that were similarly altered in both models, represented by branched-chain amino acids (BCAA) as well as glycine, serine, trans-4-hydroxyproline, and various lipid species and derivatives. Correlation analyses showed stronger associations for plasma amino acids with adipose tissue metabolites in db/db mice compared with ob/ob mice, suggesting a prominent contribution of adipose tissue to changes in plasma in a diabetic state. CONCLUSIONS/ INTERPRETATION: By studying mice with metabolite signatures that resemble obesity and diabetes in humans, we have found new metabolite entities for validation in appropriate human cohorts and revealed their possible tissue of origin.
AIMS/HYPOTHESIS: Metabolomics approaches in humans have identified around 40 plasma metabolites associated with insulin resistance (IR) and type 2 diabetes, which often coincide with those for obesity. We aimed to separate diabetes-associated from obesity-associated metabolite alterations in plasma and study the impact of metabolically important tissues on plasma metabolite concentrations. METHODS: Two obesemouse models were studied; one exclusively with obesity (ob/ob) and another with type 2 diabetes (db/db). Both models have impaired leptin signalling as a cause for obesity, but the different genetic backgrounds determine the susceptibility to diabetes. In these mice, we profiled plasma, liver, skeletal muscle and adipose tissue via semi-quantitative GC-MS and quantitative liquid chromatography (LC)-MS/MS for a wide range of metabolites. RESULTS: Metabolite profiling identified 24 metabolites specifically associated with diabetes but not with obesity. Among these are known markers such as 1,5-anhydro-D-sorbitol, 3-hydroxybutyrate and the recently reported marker glyoxylate. New metabolites in the diabetic model were lysine, O-phosphotyrosine and branched-chain fatty acids. We also identified 33 metabolites that were similarly altered in both models, represented by branched-chain amino acids (BCAA) as well as glycine, serine, trans-4-hydroxyproline, and various lipid species and derivatives. Correlation analyses showed stronger associations for plasma amino acids with adipose tissue metabolites in db/db mice compared with ob/ob mice, suggesting a prominent contribution of adipose tissue to changes in plasma in a diabetic state. CONCLUSIONS/ INTERPRETATION: By studying mice with metabolite signatures that resemble obesity and diabetes in humans, we have found new metabolite entities for validation in appropriate human cohorts and revealed their possible tissue of origin.
Authors: Christopher B Newgard; Jie An; James R Bain; Michael J Muehlbauer; Robert D Stevens; Lillian F Lien; Andrea M Haqq; Svati H Shah; Michelle Arlotto; Cris A Slentz; James Rochon; Dianne Gallup; Olga Ilkayeva; Brett R Wenner; William S Yancy; Howard Eisenson; Gerald Musante; Richard S Surwit; David S Millington; Mark D Butler; Laura P Svetkey Journal: Cell Metab Date: 2009-04 Impact factor: 27.287
Authors: Andrew C Shin; Martin Fasshauer; Nika Filatova; Linus A Grundell; Elizabeth Zielinski; Jian-Ying Zhou; Thomas Scherer; Claudia Lindtner; Phillip J White; Amanda L Lapworth; Olga Ilkayeva; Uwe Knippschild; Anna M Wolf; Ludger Scheja; Kevin L Grove; Richard D Smith; Wei-Jun Qian; Christopher J Lynch; Christopher B Newgard; Christoph Buettner Journal: Cell Metab Date: 2014-10-09 Impact factor: 27.287
Authors: Yun Wang; Daniela Botolin; Jinghua Xu; Barbara Christian; Ernestine Mitchell; Bolleddula Jayaprakasam; Muraleedharan G Nair; Muraleedharan Nair; Jeffrey M Peters; Jeffery M Peters; Julia V Busik; Julia Busik; L Karl Olson; Donald B Jump Journal: J Lipid Res Date: 2006-06-21 Impact factor: 5.922
Authors: Joshua A Beckman; Jiun-Ruey Hu; Shi Huang; Eric Farber-Eger; Quinn S Wells; Thomas J Wang; Robert E Gerszten; Jane F Ferguson Journal: Clin Sci (Lond) Date: 2020-09-18 Impact factor: 6.124
Authors: Indumathi Chennamsetty; Michael Coronado; Kévin Contrepois; Mark P Keller; Ivan Carcamo-Orive; John Sandin; Giovanni Fajardo; Andrew J Whittle; Mohsen Fathzadeh; Michael Snyder; Gerald Reaven; Alan D Attie; Daniel Bernstein; Thomas Quertermous; Joshua W Knowles Journal: Cell Rep Date: 2016-10-04 Impact factor: 9.423
Authors: Shelly R Nason; Teayoun Kim; Jessica P Antipenko; Brian Finan; Richard DiMarchi; Chad S Hunter; Kirk M Habegger Journal: Endocrinology Date: 2020-01-01 Impact factor: 4.736
Authors: Jennifer Lee; Archana Vijayakumar; Phillip J White; Yuping Xu; Olga Ilkayeva; Christopher J Lynch; Christopher B Newgard; Barbara B Kahn Journal: Endocrinology Date: 2021-07-01 Impact factor: 4.736